NASDAQ : SCNI
Scinai Immunotherapeutics Ltd. — Financial statements
Healthcare · Biotechnology · Israel
Last price 0.4716 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 268.82K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Scinai Immunotherapeutics Ltd. (SCNI) reported revenue of 1.49M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 1.49M | 1.31M | 658.00K | |||
| Cost of Revenue | 5.24M | 3.96M | 1.24M | |||
| Gross Profit | -3.75M | -2.65M | -580.00K | |||
| Selling, General & Admin | 2.67M | 2.52M | 2.53M | 4.50M | 5.30M | 7.62M |
| Research & Development | 1.97M | 2.37M | 5.53M | 5.21M | 5.76M | 3.25M |
| Other Operating Expenses | -9.00K | -12.00K | ||||
| Operating Expenses | 4.64M | 4.89M | 8.06M | 9.71M | 11.06M | 10.86M |
| Operating Income | -8.39M | -7.54M | -8.64M | -9.71M | -11.06M | -10.86M |
| Interest Expense | -202.00K | -359.00K | -1.42M | -3.80M | ||
| Interest & Investment Income | 20.00K | 20.00K | 100.00K | 3.92M | 3.05M | 3.15M |
| Currency Exchange Gain (Loss) | -419.00K | -419.00K | -84.00K | -933.00K | 1.52M | -487.00K |
| Other Non Operating Income (Expenses) | -7.00K | -7.00K | 81.00K | 4.02M | 690.00K | -9.00K |
| EBT Excluding Unusual Items | -9.00M | -8.31M | -9.96M | -6.50M | -5.80M | -8.21M |
| Other Unusual Items | 6.40M | 14.76M | ||||
| Pretax Income | -2.60M | -8.31M | 4.80M | -6.50M | -5.80M | -8.21M |
| Net Income | -2.60M | -8.31M | 4.80M | -6.50M | -5.80M | -8.21M |
| Preferred Dividends & Other Adjustments | 4.80M | |||||
| Net Income to Common | -2.60M | -8.31M | -6.50M | -5.80M | -8.21M | |
| Shares Outstanding (Basic) | 531.30K | 233.49K | 80.64K | 39.07K | 18.85K | 14.11K |
| Shares Outstanding (Diluted) | 531.30K | 233.49K | 80.64K | 39.07K | 18.85K | 14.11K |
| EPS (Basic) | -4.89 | -35.58 | -166.39 | -307.45 | -581.41 | |
| EPS (Diluted) | -4.89 | -35.58 | -166.39 | -307.45 | -800.00 | |
| Free Cash Flow | -7.50M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Free Cash Flow Per Share | -14.12 | -25.93 | -78.71 | -256.46 | -429.72 | -535.99 |
| Gross Margin | -252.32% | -202.29% | -88.15% | |||
| Operating Margin | -564.36% | -575.29% | -1,312.77% | |||
| Profit Margin | -174.78% | -633.64% | ||||
| Free Cash Flow Margin | -504.57% | -461.86% | -964.59% | |||
| EBITDA | -6.64M | -6.12M | -6.99M | -9.19M | -10.50M | -10.39M |
| D&A For EBITDA | 1.76M | 1.42M | 1.65M | 514.00K | 562.00K | 471.00K |
| EBIT | -8.39M | -7.54M | -8.64M | -9.71M | -11.06M | -10.86M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.65M | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Cash & Short-Term Investments | 2.65M | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Accounts Receivable | 74.00K | 73.00K | 83.00K | |||
| Other Receivables | 95.00K | 134.00K | 366.00K | 110.00K | 98.00K | |
| Receivables | 74.00K | 168.00K | 217.00K | 366.00K | 110.00K | 98.00K |
| Prepaid Expenses | 561.00K | 75.00K | 79.00K | 71.00K | 45.00K | 228.00K |
| Restricted Cash | 199.00K | 150.00K | 131.00K | 140.00K | 140.00K | 143.00K |
| Total Current Assets | 3.49M | 2.05M | 2.39M | 5.45M | 14.37M | 17.84M |
| Property, Plant & Equipment | 13.69M | 9.57M | 11.06M | 12.03M | 12.70M | 14.19M |
| Total Assets | 17.18M | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Accounts Payable | 844.00K | 407.00K | 376.00K | 535.00K | 716.00K | 999.00K |
| Accrued Expenses | 759.00K | 781.00K | 849.00K | 1.24M | 1.07M | |
| Current Portion of Leases | 369.00K | 329.00K | 424.00K | 396.00K | 382.00K | 375.00K |
| Current Unearned Revenue | 90.00K | 225.00K | ||||
| Total Current Liabilities | 2.23M | 1.58M | 1.81M | 1.78M | 2.34M | 2.44M |
| Long-Term Debt | 285.00K | 294.00K | 260.00K | 19.37M | 20.08M | 27.16M |
| Long-Term Leases | 2.93M | 1.64M | 1.40M | 797.00K | 1.08M | 1.45M |
| Other Long-Term Liabilities | 3.00K | 96.00K | 5.33M | |||
| Total Liabilities | 5.44M | 3.52M | 3.47M | 22.04M | 28.83M | 31.05M |
| Additional Paid-In Capital | 132.52M | 130.06M | 123.63M | 119.51M | 116.08M | 113.08M |
| Retained Earnings | -124.27M | -125.85M | -117.54M | -122.33M | -115.83M | -110.04M |
| Comprehensive Income & Other | -2.14M | -1.74M | -1.74M | -1.74M | -2.01M | -2.06M |
| Total Common Equity | 6.11M | 2.48M | 4.35M | -4.57M | -1.76M | 982.00K |
| Shareholders' Equity | 11.73M | 8.10M | 9.98M | -4.57M | -1.76M | 982.00K |
| Total Liabilities & Equity | 17.18M | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Total Debt | 3.58M | 2.27M | 2.09M | 20.56M | 21.54M | 28.98M |
| Net Cash (Debt) | -926.00K | -606.00K | -122.00K | -15.69M | -7.47M | -11.61M |
| Net Cash Per Share | -1.74 | -2.60 | -1.51 | -401.65 | -396.09 | -822.66 |
| Filing Date Shares Outstanding | 570.02K | 346.82K | 85.30K | 46.43K | 32.84K | 18.83K |
| Total Common Shares Outstanding | 570.02K | 346.82K | 85.30K | 46.43K | 32.84K | 18.83K |
| Working Capital | 1.26M | 469.00K | 585.00K | 3.67M | 12.03M | 15.40M |
| Book Value Per Share | 10.71 | 7.14 | 51.00 | -98.41 | -53.59 | 52.16 |
| Tangible Book Value | 6.11M | 2.48M | 4.35M | -4.57M | -1.76M | 982.00K |
| Tangible Book Value Per Share | 10.71 | 7.14 | 51.00 | -98.41 | -53.59 | 52.16 |
| Machinery | 9.95M | 9.92M | 2.46M | 1.92M | 1.23M | |
| Construction In Progress | 7.45M | 7.83M | 8.86M | |||
| Leasehold Improvements | 3.72M | 3.72M | 3.72M | 3.92M | 4.43M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -2.60M | -8.31M | 4.80M | -6.50M | -5.80M | -8.21M |
| Depreciation & Amortization | 1.76M | 1.42M | 1.65M | 514.00K | 562.00K | 471.00K |
| Asset Writedown & Restructuring Costs | 209.00K | |||||
| Stock-Based Compensation | 161.00K | 303.00K | 682.00K | 1.14M | 1.60M | 2.76M |
| Other Operating Activities | -6.05M | 389.00K | -13.57M | -3.74M | -4.11M | -3.15M |
| Change in Accounts Receivable | 195.00K | 10.00K | -83.00K | 59.00K | ||
| Change in Accounts Payable | 12.00K | 31.00K | -156.00K | -150.00K | -175.00K | 3.00K |
| Change in Other Net Operating Assets | -847.00K | 122.00K | 351.00K | -646.00K | 446.00K | 642.00K |
| Operating Cash Flow | -7.38M | -6.03M | -6.33M | -9.38M | -7.26M | -7.43M |
| Capital Expenditures | -127.00K | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Investing Cash Flow | 2.62M | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Issuance of Common Stock | 4.19M | 5.77M | 1.44M | 1.09M | 6.78M | 21.43M |
| Other Financing Activities | 2.32M | 2.00M | ||||
| Financing Cash Flow | 6.51M | 5.77M | 3.44M | 1.09M | 6.78M | 21.43M |
| Foreign Exchange Rate Adjustments | -41.00K | 1.00K | -9.00K | -272.00K | -1.98M | 575.00K |
| Net Cash Flow | 1.72M | -284.00K | -2.92M | -9.21M | -3.30M | 14.44M |
| Free Cash Flow | -7.50M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Free Cash Flow Margin | -504.57% | -461.86% | -964.59% | |||
| Free Cash Flow Per Share | -14.12 | -25.93 | -78.71 | -256.46 | -429.72 | -535.99 |
| Levered Free Cash Flow | -3.66M | -3.33M | -3.82M | -8.28M | -5.52M | -2.71M |
| Unlevered Free Cash Flow | -3.53M | -3.10M | -2.93M | -5.90M | -5.52M | -2.71M |
| Free Cash Flow After Leases | -7.50M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Cash Interest Paid | 143.00K | 833.00K | 916.00K | |||
| Change in Working Capital | -640.00K | 163.00K | 112.00K | -796.00K | 271.00K | 704.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 268.82K | 2.47M | 2.85M | 2.59M | 10.32M | 43.42M |
| Enterprise Value | 1.19M | 9.46M | 3.05M | 16.04M | 19.46M | 54.73M |
| Last Close Price | 0.47 | 7.12 | 33.45 | 59.54 | 296.00 | 2,350.00 |
| PS Ratio | 0.18 | 1.88 | 4.34 | |||
| PB Ratio | 0.04 | 0.30 | 0.29 | -0.57 | -5.86 | 44.21 |
| P/TBV Ratio | 0.04 | 1.00 | 0.66 | 44.21 | ||
| EV/Sales Ratio | 0.80 | 7.22 | 4.63 | |||
| Debt / Equity Ratio | 0.30 | 0.28 | 0.21 | -4.50 | -12.24 | 29.52 |
| Net Debt / Equity Ratio | 0.08 | 0.07 | 0.01 | -3.43 | -4.24 | 11.82 |
| Net Debt / EBITDA Ratio | -0.14 | -0.10 | -0.02 | -1.71 | -0.71 | -1.12 |
| Net Debt / FCF Ratio | -0.12 | -0.10 | -0.02 | -1.57 | -0.92 | -1.53 |
| Asset Turnover | 0.10 | 0.10 | 0.04 | |||
| Quick Ratio | 1.22 | 1.15 | 1.21 | 2.94 | 6.07 | 7.15 |
| Current Ratio | 1.56 | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 |
| Return on Equity (ROE) | -26.53% | -91.89% | 177.37% | |||
| Return on Assets (ROA) | -36.15% | -37.60% | -34.92% | -27.24% | -23.39% | -26.97% |
| Return on Capital Employed (ROCE) | -56.20% | -75.10% | -74.20% | -61.90% | -44.70% | -36.70% |
| Earnings Yield | -2,956.01% | -336.35% | 168.09% | -250.86% | -56.18% | -18.90% |
| FCF Yield | -2,791.07% | -245.17% | -222.45% | -386.67% | -78.52% | -17.42% |
| Buyback Yield / Dilution | -303.74% | -189.55% | -106.41% | -107.22% | -33.57% | -27.36% |